Radiotherapy in Pancreatic Cancer: To Whom, When, and How?
The diagnosis rate of pancreatic cancer is steadily increasing. The average age of onset is close to 70 years. In most cases, the disease is diagnosed at an advanced stage. The indications for and techniques of radiotherapy are changing over time. The aim of this thesis is to present the role and po...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/13/3382 |
| _version_ | 1797591976615346176 |
|---|---|
| author | Michał Falco Bartłomiej Masojć Tadeusz Sulikowski |
| author_facet | Michał Falco Bartłomiej Masojć Tadeusz Sulikowski |
| author_sort | Michał Falco |
| collection | DOAJ |
| description | The diagnosis rate of pancreatic cancer is steadily increasing. The average age of onset is close to 70 years. In most cases, the disease is diagnosed at an advanced stage. The indications for and techniques of radiotherapy are changing over time. The aim of this thesis is to present the role and possibilities of radiotherapy from the perspective of radiation oncologist. The most common cause of treatment failure in pancreatic cancer remains generalisation. The implementation of new systemic treatment regimens contributes to improved treatment outcomes regardless of the stage of the disease. With improved treatment outcomes in terms of the incidence of distant metastases, the impact of local curability on the length and quality of life of patients increases. Modern radiotherapy offers the opportunity to achieve high local cure rates. Postoperative radiotherapy in combination with chemotherapy seems justified in the group of postoperative pancreatic cancer patients with pT3 and pN+ features. In the group of patients with borderline resectable pancreatic cancer, the impact of radiotherapy in combination with the latest chemotherapy regimens is difficult to define clearly. In the setting of a diagnosis of advanced pancreatic cancer, radiotherapy, especially stereotactic radiotherapy, in combination with chemotherapy, contributes to improved local curability and allows to achieve a significantly reduced level of pain. |
| first_indexed | 2024-03-11T01:45:15Z |
| format | Article |
| id | doaj.art-82e97dce18ba497d9e1f1f5571133f68 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T01:45:15Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-82e97dce18ba497d9e1f1f5571133f682023-11-18T16:16:12ZengMDPI AGCancers2072-66942023-06-011513338210.3390/cancers15133382Radiotherapy in Pancreatic Cancer: To Whom, When, and How?Michał Falco0Bartłomiej Masojć1Tadeusz Sulikowski2Radiation Oncology Department, West Pomeranian Oncology Center, Strzałowska 22, 71-730 Szczecin, PolandRadiation Oncology Department, West Pomeranian Oncology Center, Strzałowska 22, 71-730 Szczecin, PolandDepartment of General, Minimally Invasive, and Gastroenterological Surgery, Pomeranian Medical University in Szczecin, 71-252 Szczecin, PolandThe diagnosis rate of pancreatic cancer is steadily increasing. The average age of onset is close to 70 years. In most cases, the disease is diagnosed at an advanced stage. The indications for and techniques of radiotherapy are changing over time. The aim of this thesis is to present the role and possibilities of radiotherapy from the perspective of radiation oncologist. The most common cause of treatment failure in pancreatic cancer remains generalisation. The implementation of new systemic treatment regimens contributes to improved treatment outcomes regardless of the stage of the disease. With improved treatment outcomes in terms of the incidence of distant metastases, the impact of local curability on the length and quality of life of patients increases. Modern radiotherapy offers the opportunity to achieve high local cure rates. Postoperative radiotherapy in combination with chemotherapy seems justified in the group of postoperative pancreatic cancer patients with pT3 and pN+ features. In the group of patients with borderline resectable pancreatic cancer, the impact of radiotherapy in combination with the latest chemotherapy regimens is difficult to define clearly. In the setting of a diagnosis of advanced pancreatic cancer, radiotherapy, especially stereotactic radiotherapy, in combination with chemotherapy, contributes to improved local curability and allows to achieve a significantly reduced level of pain.https://www.mdpi.com/2072-6694/15/13/3382advanced pancreatic cancerborderline resectable cancerradiotherapyradiochemotherapystereotactic radiotherapy |
| spellingShingle | Michał Falco Bartłomiej Masojć Tadeusz Sulikowski Radiotherapy in Pancreatic Cancer: To Whom, When, and How? Cancers advanced pancreatic cancer borderline resectable cancer radiotherapy radiochemotherapy stereotactic radiotherapy |
| title | Radiotherapy in Pancreatic Cancer: To Whom, When, and How? |
| title_full | Radiotherapy in Pancreatic Cancer: To Whom, When, and How? |
| title_fullStr | Radiotherapy in Pancreatic Cancer: To Whom, When, and How? |
| title_full_unstemmed | Radiotherapy in Pancreatic Cancer: To Whom, When, and How? |
| title_short | Radiotherapy in Pancreatic Cancer: To Whom, When, and How? |
| title_sort | radiotherapy in pancreatic cancer to whom when and how |
| topic | advanced pancreatic cancer borderline resectable cancer radiotherapy radiochemotherapy stereotactic radiotherapy |
| url | https://www.mdpi.com/2072-6694/15/13/3382 |
| work_keys_str_mv | AT michałfalco radiotherapyinpancreaticcancertowhomwhenandhow AT bartłomiejmasojc radiotherapyinpancreaticcancertowhomwhenandhow AT tadeuszsulikowski radiotherapyinpancreaticcancertowhomwhenandhow |